Copy Link Print Information

T0070907

45 Cited Publications
Kundenbewertung

Based on 45 publication(s) in Google Scholar

T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.94%
  • CAS. Nr.: 313516-66-4
  • Formel: C12H8ClN3O3
  • Molecular Weight:277.66
  • Speicherung:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • T0070907 Chemical Structure
    T0070907 Chemical Structure
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
CAS. Nr.: 313516-66-4
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of T0070907:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) T0070907

More
Customer Validation & Images
Cell Proliferation/Viability AssayRT-PCRIn Vivo Efficacy StudyWBFlow Cytometry
  • RT-PCR
  • WB
  • Flow Cytometry
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay

Alle PPAR Isoform-spezifische Produkte anzeigen

More
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • T0070907 Chemical Structure
    T0070907 Chemical Structure
    1/16
  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]

    Customer Validation
     NECTIN4 mRNA levels in RT112 cells treated with 1 μM Rosiglitazone and T0070907 (T007) for 72 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]

    Customer Validation
     T0070907 (0.5-2.5 μM; 72 h). Western blot for NECTIN4 and HPGD in RT112 cells treated with T0070907, Rosiglitazone, and Pioglitazone at indicated concentrations for 72 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]

    Customer Validation
     NECTIN4 surface staining in RT112 cells treated with 1 μM Rosiglitazone and T0070907 for 72 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]

    Customer Validation
     T0070907 (10 µM; 1 µL per side; microinjected into the mPFC). The social interaction ratio of mice from control, SUS-vehicle, SUS-vehicle-pioglitazone, SUS-T0070907-pioglitazone groups.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2024 Apr:102:105079. [Abstract]

    Customer Validation
     T0070907 (0-15 μM; 24 h). Viability of HepG2 cells treated with 400 μM PA and indicated concentrations of T0070907 for 24 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

    Customer Validation
     HT22 cells were pretreated with the indicated inhibitors (CDDO (Bardoxolone, HY-14909); T0070907 (HY-13202); Troglitazone (HY-50935 ); TPCA-1 (HY-10074); JAKi; STAT3i; AV-412 (HY-10346); and MK2206 (HY-10358)) and then treated with T/Z, T/S/Z, T/C/Z for 9 h or Glutamate, Erastin (T: 20 ng/ml; Z: 50 μM; S: 20 nM; C: 1 μg/ml; Glutamate: 50 mM; Erastin 10 μM) for 12 h. Cell viability was measured by CellTiterGlo assay.

  • T0070907